Skin cancer vaccine BLA submitted by June 30, 2027?
Probability
88¢
1h
+0.0pp
24h
+0.0pp
24h Vol
$3.1K
Liquidity
$3.6K
Canonical status
confidence: highSource status (Polymarket)
Derived status (Orrery)
Reason
Active market, expiry beyond the near-expiry window.
Resolution & Risk
LOW risk- End date
- Jun 30, 2027
- UMA status
- n/a
- Resolution source
- Primaryconsensus of credible reportingTypeNews consensusConfidenceextracted · medium
- Market type
- Binary
- No obvious resolution-risk signals in metadata.
Probability (last 7 days)
+0.0pp 7dWhy did it move?
Structured · 1 factor- 01Liquidity
Thin liquidity
Only $3.6k of visible book — small orders can move the line. Treat the probability as a soft estimate.
What to track next
- Set an alert at the next ±5pp probability move so you find out before the next leg.
- Add to your watchlist — Home will show probability deltas since your last visit.
- Compare against sibling markets in the same event below — divergent pricing across related contracts is the cleanest tell.
Verification actions only — never trade recommendations.
Each factor is grounded in a single named metric you can verify on this page — probability, volume, liquidity, signal, resolution state. No predictions, no prose hallucinations.
Resolution & Risk
LOW risk- End date
- Jun 30, 2027
- UMA status
- n/a
- Resolution source
- Primaryconsensus of credible reportingTypeNews consensusConfidenceextracted · medium
- Market type
- Binary
- No obvious resolution-risk signals in metadata.
Verification Brief
A guided checklist for what must be proven before this market is treated as reliable context.
The market is live. Track source, liquidity, and wording before escalating it to a resolution-sensitive task.
Create trust-state alertVerification goal
Map resolution-relevant sources to the exact criteria needed to avoid misreading price as settlement.
What needs proof
Primary source
requiredConfirm the primary news consensus source and whether it directly answers the market's resolution question.
Current evidence: consensus of credible reporting
Contract wording
requiredExtract the exact condition that makes YES resolve true and note any exclusions, time zone, deadline, or fallback rule.
Orrery verification task Skin cancer vaccine BLA submitted by June 30, 2027? State: Live — live monitoring Need sources for: 1. Primary source: Confirm the primary news consensus source and whether it directly answers the market's resolution question. 2. Contract wording: Extract the exact condition that makes YES resolve true and note any exclusions, time zone, deadline, or fallback rule. 3. Liquidity context: Check whether the move is supported by enough liquidity and volume to treat it as meaningful context. Drop only durable links that map to one criterion. Research only. Not trade advice.
Orrery verification brief Skin cancer vaccine BLA submitted by June 30, 2027? State: live monitoring Verify: Primary source + Contract wording Price is not settlement. Research only. Not trade advice.
Market link goes in reply
A controlled loop for durable sources. Every source must answer one criterion from this Verification Brief.
Sources
0
Criteria covered
0
Reviewed
0
Awaiting review
0
Submit a source mapped to a criterion
Recent source checks
Pilot audit summary
Research only · Not trade advice · Every source maps to one criterion
Timeline
critical · price · trade flowCritical
- Jun 30, 23:59 UTCScheduled resolutionLOW
Market resolves in 7561.5h
Price movement
+0.0pp over the last 24h, now 88¢.
Recent Trades
No recent trades visible from the Data API for this market. That usually means liquidity is thin or this market is between event windows.
Market Description
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Why this category?
confidence: mediumCategory
Source
Matched term
vaccineReason
Question text contains "vaccine" — matched the Science keyword rule.
Categories come from a deterministic engine: manual overrides (highest priority) → sports hard markers → event-tag rules → keyword rules → Gamma category hint → default. The engine is versioned in category-overrides.ts; methodology lives at /methodology.
FAQ — questions readers actually ask
What is the current Polymarket probability for "Skin cancer vaccine BLA submitted by June 30, 2027?"?
As of Wed, 19 Aug 2026 22:28:49 GMT, YES is priced at 88% implied probability on Polymarket. The price changed +0.0pp in the last 24 hours, +0.0pp in the last hour, and +0.0pp in the last 7 days.
When does this market resolve?
This market resolves by Jun 30, 2027 (2027-06-30T23:59:00.000Z). Resolution is determined from the market description on Polymarket.
What source determines the outcome?
Resolution is sourced from the market description on Polymarket. Polymarket's UMA optimistic oracle is the final settlement layer; if the published source is ambiguous, UMA tokenholders adjudicate. Source-extraction confidence is shown in the Resolution & Risk block above.
How much is being traded on this market?
$3.1K of trading volume in the last 24 hours. Lifetime volume on Polymarket: $3.1K. Open liquidity in the YES/NO orderbooks: $3.6K. Spread between best bid and best ask: 1.0¢.
Is this a trade recommendation?
No. Orrery describes — never predicts. Every signal on this market carries explicit Evidence, Backtest, and Action tiers. The Action is always one of: Watch only, Inspect timeline, Create alert, Verify source, or Ignore — never Buy or Sell. The probability above is the market's collective implied probability, not a forecast Orrery is publishing.
How fresh is this data and where does it come from?
This page revalidates from the public Polymarket APIs every 30 seconds. Probability and 24h-change come from Gamma; the chart series comes from the CLOB orderbook history; trade and holder data come from the Data API. The fetched-at timestamp on each block tells you exactly how old the underlying upstream pull was.
Alerts
In-app banners fire as soon as a rule is satisfied. Email digests are wired to a server-side cron and continue while your tabs are closed. Telegram and Discord are planned — every existing rule will keep working as channels light up.